Last reviewed · How we verify

Raloxifene HCL

Eli Lilly and Company · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Raloxifene HCL is a Small molecule drug developed by Eli Lilly and Company. It is currently FDA-approved. Also known as: Evista, LY139481.

Raloxifene HCL is a small molecule used in the treatment of postmenopausal osteoporosis and breast cancer, as well as other conditions such as perimenopausal depression and schizophrenia in postmenopausal women. It has been studied in combination with teriparatide and alendronate in clinical trials.

At a glance

Generic nameRaloxifene HCL
Also known asEvista, LY139481
SponsorEli Lilly and Company
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Raloxifene HCL

What is Raloxifene HCL?

Raloxifene HCL is a Small molecule drug developed by Eli Lilly and Company.

Who makes Raloxifene HCL?

Raloxifene HCL is developed and marketed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).

Is Raloxifene HCL also known as anything else?

Raloxifene HCL is also known as Evista, LY139481.

What development phase is Raloxifene HCL in?

Raloxifene HCL is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing